Premium
The American cockroach peptide periplanetasin‐4 inhibits Clostridium difficile toxin A‐induced cell toxicities and inflammatory responses in the mouse gut
Author(s) -
Yoon I Na,
Lu Li Fang,
Hong Ji,
Zhang Peng,
Kim Dae Hong,
Kang Jin Ku,
Hwang Jae Sam,
Kim Ho
Publication year - 2017
Publication title -
journal of peptide science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 66
eISSN - 1099-1387
pISSN - 1075-2617
DOI - 10.1002/psc.3046
Subject(s) - toxin , clostridium difficile toxin a , pseudomembranous colitis , apoptosis , microbiology and biotechnology , transcriptome , biology , clostridium difficile , peptide , inflammation , cockroach , clostridium difficile toxin b , viability assay , programmed cell death , immunology , biochemistry , antibiotics , gene expression , gene , ecology
Many reports have shown that crude extracts of the American cockroach have therapeutic effects on inflammation. In a previous study, our research group showed that an antimicrobial peptide (Periplanetasin‐2) derived from the American cockroach via de novo transcriptome analysis inhibited apoptosis of human colonocytes and inflammatory responses of the mouse gut caused by Clostridium difficile toxin A. Here, we examined whether Periplanetasin‐4 (Peri‐4), another antimicrobial peptide identified via de novo transcriptome analysis of the American cockroach, could also inhibit the various toxicities induced by C. difficile toxin A. We found that Peri‐4 significantly reduced the cell viability loss and cell apoptosis caused by toxin A in vitro . Peri‐4 also ameliorated the severe inflammatory responses seen in the toxin A‐induced mouse enteritis model, rescuing the villus disruption and interleukin‐6 production induced by luminal injection of toxin A into the mouse gut. Mechanistically, we found that Peri‐4 could reduce toxin A‐induced reactive oxygen species production to inhibit the activations of p38MAPK and p21 Cip1/Waf1 , which are critical for the cell damages induced by toxin A. These results collectively suggest that the Peri‐4 may be a potential therapeutic agent for treating toxin A‐induced pseudomembranous colitis. Copyright © 2017 European Peptide Society and John Wiley & Sons, Ltd.